Login to Your Account



American Society Of Clinical Oncology

Positive Sorafenib Data Lead To Analyst Downgrade, Stock Drop

By Anette Breindl


Tuesday, May 17, 2005
Many a biotechnology company can tell war stories of negative Phase III data, followed by analyst downgrades and a decline in stock price. But Onyx Pharmaceuticals Inc. had what is arguably an even more frustrating tale to tell: positive Phase III data, followed by an analyst downgrade and a decline in stock price. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription